Friday, 16 October 2026European Markets

TOYOTA CAETANO And ELOPAK Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(VIANEWS) - TOYOTA CAETANO (SCT.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Cyclical sector.

Financial Asset Price Forward Dividend Yield Return on Equity
TOYOTA CAETANO (SCT.LS) €5.00 5.53% 9.52%
ELOPAK (ELO.OL) kr22.20 4.04% 19.73%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. TOYOTA CAETANO (SCT.LS)

5.53% Forward Dividend Yield and 9.52% Return On Equity

Toyota Caetano Portugal, S.A. imports, assembles, and commercializes light and heavy vehicles. It offers commercial and passenger cars, as well as parts; cargo handling machines; and mini-buses. The company also sells and rents industrial equipment, including counterweight forklift trucks and warehouse equipment; provides technical after-sales assistance; incorporates components into commercial vehicles; and offers business services and solutions, such as short-term rental, used and reconditioned assistance, maintenance contracts sale of parts, and fleet management of related equipment. It distributes its products under the Toyota and Lexus brand names in Portugal, Belgium, African countries, Spain, Germany, the United Kingdom, and internationally. The company was incorporated in 1946 and is headquartered in Vila Nova de Gaia, Portugal. Toyota Caetano Portugal, S.A. is a subsidiary of Salvador Caetano Auto (S.G.P.S.), S.A.

Earnings Per Share

As for profitability, TOYOTA CAETANO has a trailing twelve months EPS of €0.33.

PE Ratio

TOYOTA CAETANO has a trailing twelve months price to earnings ratio of 15.15. Meaning, the purchaser of the share is investing €15.15 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.52%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 485.44M for the twelve trailing months.

More news about TOYOTA CAETANO.

2. ELOPAK (ELO.OL)

4.04% Forward Dividend Yield and 19.73% Return On Equity

Elopak ASA manufactures and supplies paper-based packaging solutions for liquid food in Norway and internationally. It offers Pure-Pak cartons for chilled and aseptic applications; common roll fed aseptic carton; and packaging products. It also provides packaging solutions for detergent, fabric softener, and hand wash products. In addition, the company offers standard flexo, super flexo, UV-flexo, and offset litho printing services, as well as digital print proofs and machine print proofs on paper board. Further, it provides machine and equipment through spare part webshop. Elopak ASA was founded in 1957 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, ELOPAK has a trailing twelve months EPS of kr2.26.

PE Ratio

ELOPAK has a trailing twelve months price to earnings ratio of 9.82. Meaning, the purchaser of the share is investing kr9.82 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.73%.

Sales Growth

ELOPAK's sales growth is negative 90.4% for the ongoing quarter and negative 90.9% for the next.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on May 12, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 4.04%.

Moving Average

ELOPAK's value is under its 50-day moving average of kr22.81 and below its 200-day moving average of kr23.48.

Volume

Today's last reported volume for ELOPAK is 2684 which is 97.32% below its average volume of 100240.

More news about ELOPAK.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com